2 Quantum Stocks With 75%+ Upside in August After Q2 Earnings

The quantum computing industry made further progress toward commercialization in the second quarter of 2026, with enterprise adoption, government support and capital availability strengthening across the space. McKinsey's April 2026 Quantum Technology Monitor points to accelerating commercialization, with more than 300 organizations worldwide engaging with quantum computing and early movers transitioning from pilots to applications embedded in end-to-end workflows.

The report also found that one-third of the large global companies it analyzed allocated more than $10 million to quantum computing initiatives in 2025, with spending focused largely on use-case development, integration with existing technology stacks and internal capabilities.

The quarter also saw significant developments in commercial infrastructure and funding. IonQ’s IONQ 60% of second-quarter revenues came from commercial customers. IonQ also made progress on its 256-qubit system, quantum error correction, quantum networking and the integration of SkyWater Technology and Nexus Photonics into its full-stack strategy. D-Wave's QBTS 62.4% of second-quarter revenues came from commercial customers, up from 45.1% a year earlier. More significantly, first-half bookings reached $35.5 million, up 1,120% year over year, including a $20 million system sale, while remaining performance obligations rose 668% to $40.7 million.

Against this backdrop, two stocks stand out in August for their more than 75% short-term price-target upside following their second-quarter releases. These are  Quantum Computing Inc. QUBT or QCi and Quantinuum QNT.

Image Source: Zacks Investment Research

Quantum Stocks Rally in Q2 & Then Face a Sharp July Reset

The markets reflected this improving commercial narrative during April-June. The Defiance Quantum ETF QTUM rallied 51.3% over the April to June period, banking on the consolidated gains that came as investors increasingly focused on bookings, system sales, enterprise partnerships and technology milestones rather than quantum computing's longer-term potential alone. The June IPO of Quantinuum added another important development to the public-market landscape, with the company raising $1.68 billion and becoming one of the largest publicly traded pure-play quantum companies.

However, the strong second-quarter rally quickly gave way to a broad reset in July, as shown in the following chart. The decline followed substantial gains in the preceding quarter and reflected high valuation sensitivity of speculative technology stocks.

Share Price Performance in July

Image Source: Zacks Investment Research

August Positioning: Fundamentals Are Becoming More Important

The major pure plays have now reported second-quarter results, giving investors more evidence on revenue growth, customer adoption, liquidity and technology execution. D-Wave's second-quarter revenues missed expectations despite a sharp increase in bookings, while Rigetti reported strong revenue growth. IonQ also reported substantial revenue growth. The results showed a key shift in the sector. Investors are increasingly looking for evidence of commercial conversion rather than relying solely on technology milestones.

2 Stocks with 75%+ Target Price in August

QCi: Quantum Computing enters the second half of 2026 with several potential growth drivers. In the near term, the Dirac-3 deployment, NeuraWave’s commercial readiness and its Planck Dynamics agreement could expand customer adoption, with the latter carrying potential program value above $10 million subject to milestones. The $42.5 million backlog and $1.3 billion cash position provide funding for continued execution. For the longer term, the NHanced acquisition and the launch of Fab 2 expand QCi’s advanced packaging and semiconductor manufacturing capabilities, supporting its strategy to scale photonic and quantum technologies. The key catalysts will be converting these deployments into recurring revenues while integrating its acquisitions and controlling rising operating costs.

Based on short-term price targets offered by six analysts, the average price target for QCi represents an increase of 104.8% from the last closing price of $8.95. QCi carries a Zacks Rank #3 (Hold).

Image Source: Zacks Investment Research

Quantinuum: The company entered the second half of 2026 with accelerating commercial activity. Second-quarter 2026 revenues jumped 279% year over year, while the company issued 2026 revenue guidance of $28-$32 million. In the near term, the Oracle partnership to deploy Helios through Oracle Cloud Infrastructure could broaden enterprise access, while its HPE collaboration targets integration of quantum computing with HPC environments. Quantinuum also demonstrated near-five-nines logical fidelity on Helios, advancing its error-correction efforts.

For the longer term, its planned Sol system in 2027 and Apollo roadmap are aimed at scaling quantum capabilities. With more than $2 billion in liquidity following its IPO, Quantinuum has substantial resources to fund this roadmap, although profitability remains a longer-term objective.

Based on short-term price targets offered by 12 analysts, the average price target for QNT represents an increase of 76.2% from the last closing price of $56.1. Quantinuum carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Image Source: Zacks Investment Research

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research